PHG

PHG

USD

Koninklijke Philips N.V. NY Registry Shares

$28.020-0.180 (-0.638%)

Real-time Price

Healthcare
Medical devices
Netherlands

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$28.200

High

$28.525

Low

$27.830

Volume

1.00M

Company Fundamentals

Market Cap

26.9B

Industry

Medical devices

Country

Netherlands

Trading Stats

Avg Volume

0.74M

Exchange

NYQ

Currency

USD

52-Week Range

Low $21.48Current $28.020High $29.29

Related News

GlobeNewswire

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA

View more
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
BusinessWire

Philips Joins the Forever Promise Project to Honor American Veterans

Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced its support of the Forever Promise Project, an initiative of the Monuments Men and Women Foundation that connects American

View more
Philips Joins the Forever Promise Project to Honor American Veterans
GlobeNewswire

Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA

October 30, 2025 10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport

View more
Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA
GlobeNewswire

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major

View more
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients